F. Hoffmann-La Roche Ltd, Abbott, Thermofisher, Seimens AG, Bio-Rad Laboratories, Inc. and others are dominating the market for Global Blood Screening Market in 2017

Hoffmann-La Roche Ltd:

Hoffmann-La Roche Ltd incorporated in 1896, headquarters in Switzerland focuses on developing innovative medicines and diagnostic tests. Company has two business segment which are pharmaceuticals and diagnostics. The company has its presence in Europe, North America, Latin America, Asia, Africa, Australia and Oceania.

• In January 2017, F. Hoffmann-La Roche Ltd, launched hematology testing solution. This solution is called the cobas m 511 integrated haematology analyser. This launch marked the entry for Roche Diagnostics in the haematology market.

Access Full Report : https://databridgemarketresearch.com/reports/global-blood-screening-market

ABBOTT:

ABBOTT, founded in 1888 is based in Illinois. The company engaged in manufacturing products for diagnostics, medical devices, nutrition and branded generic pharmaceuticals. The company has its business segments and they are established pharmaceuticals, nutritionals, diagnostics, cardiovascular and neuromodulation and others. The company has its presence in Asia Pacific, Europe, Middle East and South Africa, The Americas.

• In September 2017, Abbott achieved U.S. Food and Drug Administration approval for its product glucose monitoring device for disease called diabetes. It helped people without having to prick their fingers for testing their blood sugar levels. This helped company to increase their product portfolio in market.

Thermo Fisher Scientific Inc.:

Thermo Fisher Scientific Inc., founded in 1956 is based in Massachusetts, U.S. The company provides manufacturing, distributing and services of medical devices and pharma Services. The Company has its business segments such as laboratory products & services, life sciences solutions, analytical instruments and specialty diagnostics. The company has its presence in North America, Europe, Asia-Pacifica, and rest of World.

• In June 2018, Thermo Fisher Scientific launched Oncomine TCR Beta-SR Assay. It is a new next-generation sequencing (NGS) solution in the field of immuno-oncology research. This helped company to expand their business by enhancing their product portfolio.